Business
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine(TM) as a Promising New Anti-Inflammatory Agent
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDevonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nQUÉBEC, Dec. 4, 2025 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Corporation\") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled \"Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs.\" The study presents notable evidence supporting the potent multi-target anti-inflammatory properties of Thykamine™, the Corporation's lead pharmaceutical candidate.\n\n\n\n\n\n\n\nThe article, published in peer-reviewed BioMedicines Journal and titled, ''Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs'', is now available online at: https://www.mdpi.com/2227-9059/13/12/2938. It was co-authored by Dr. Charles Lynde, Associate Professor in the Department of Medicine at the University of Toronto; Professor (Pr) Louis Flamand, Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval; Vincent McCarty and Dr. John Sampalis, Department of Surgery, McGill University, Montreal, Canada.\nIn this study, researchers compared the effect of Thykamine™ with six widely prescribed anti-inflammatory drugs (including corticosteroids such as betamethasone, clobetasol, hydrocortisone, prednisone; and non-steroidal therapies such as crisaborole and pimecrolimus). Using an in vitro model of immune-activated cells, they measured secretion levels of major chemokines (inflammatory markers) — MCP-1, MIP-1α, MIP-1β and RANTES — after inflammatory stimulation. Thykamine™ inhibited secretion of MCP-1, MIP-1α, and MIP-1β with significantly greater potency than all comparators and suppressed RANTES secretion to a degree comparable or superior to most a...